|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS11310|
Asia-Pacific Sleeping Aids Market Overview
The Asia-Pacific sleeping aids market size was $9.3 billion in 2015 and is forecasted to grow at a CAGR of 6.6% during the period 2016-2022. Various type of sleeping disorders such as sleep apnea, insomnia, restless legs syndrome, narcolepsy and sleep walking require some or the other type of sleeping aids intervention. Sleeping aids for sleep apnea held the largest share in the Asia-Pacific market in 2015, since an increasing number of people in the region suffer from breathing problems while sleeping.
The demand for sleeping aids has been rising in the region due to high consumption of sleeping pills owing to changing lifestyle, growing awareness about sleep disorders and other related problems, long working hours, and growing aging population. Some of the sleeping aids products available in the market include mattress & pillow, sleep laboratories, medication, sleep apnea devices and others. Amongst these, mattress & pillows held the highest share in the regional market, standing at 41% in 2015, since they have a direct impact on the sleeping condition of a person.
Due to rising aging population in the region, more number of people have been dealing with sleep related problems, thus leading to increase in the sale of sleeping aids products. According to the United Nations (UN) publication, World Population Aging 2013, around 468.5 million people were aged 60 years and above in Asia-Pacific, out of which, about 57.5 million people were above 80 years of age.
Also, there are many organizations that have been creating awareness about sleep disorders such as Indian Sleep Disorder Association, Hong Kong Society of Sleep Medicine, Asia-Pacific Pediatric Sleep Alliance Asia-Pacific and others. Indian Sleep Disorders Association (ISDA) conducts a conference namely, Sleepcon conducted every year to update the society on current trends and concepts in the management of sleep disorders.
Long working hours often lead to sleep issues and the government agencies and other firms are taking action against it to improve the conditions of workers in the region. For instance, Sumitomo Mitsui Trust Bank extended its nine-hour minimum to all employees, including contract staff, in December 2016. The Japanese government has set aside about ¥400 million for the year 2017 for an incentive program to encourage small and medium-sized companies to adopt minimum rest periods to ensure better productivity. All such initiatives by the governments in various countries in the region, eventually leads to the high demand of products in the sleeping aids market in the region.
Due to increasing sleeping disorders, the players in the sleeping aids market in the region are investing more in research and development activities and development of new drugs. For instance, in October 2016, Eisai Co., Ltd. announced the initiation of a Phase II clinical study of its internally-discovered oral dual orexin receptor antagonist lemborexant in patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD) and mild to moderate Alzheimer's disease (AD) dementia. Lemborexant is being jointly developed by Eisai and Purdue Pharma L.P. There is no known treatment approved for an irregular sleep-wake pattern in patients, therefor it is a condition with high unmet medical need, further leading to the growth of the sleeping aids market in the region.
Side-effects associated with sleeping aid medications such as drug dependence and withdrawal symptoms are the some of the factors negatively impacting the demand of the sleeping aids products, thereby hindering the development of the market. Patent expiration of treatment pills for sleep disorders is another key factor that impedes the growth of the market.
Asia-Pacific Sleeping Aids Market - Competitive Landscape
Some of the other key players operating in the Asia-Pacific sleeping aids industry include Sanofi S.A., Koninklijke Philips N.V., GlaxoSmithKline PLC, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Compumedics Limited, Becton, Dickinson and Company, Eisai Co., Ltd. and Drive Medical Ltd.